

Richard S Kaplan

List of Publications by Citations

Source: <https://exaly.com/author-pdf/2485678/richard-s-kaplan-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

172
papers

28,731
citations

52
h-index

169
g-index

183
ext. papers

32,145
ext. citations

8.7
avg, IF

6.19
L-index

#	Paper	IF	Citations
172	New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. <i>Journal of the National Cancer Institute</i> , 2000 , 92, 205-16	9.7	13624
171	Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. <i>Lancet, The</i> , 2017 , 389, 815-822	40	1485
170	MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. <i>New England Journal of Medicine</i> , 2018 , 378, 1767-1777	59.2	1250
169	Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. <i>Journal of Clinical Oncology</i> , 1999 , 17, 3461-7	2.2	839
168	Participation of patients 65 years of age or older in cancer clinical trials. <i>Journal of Clinical Oncology</i> , 2003 , 21, 1383-9	2.2	800
167	Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. <i>Lancet, The</i> , 2011 , 377, 2103-14	40	762
166	Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. <i>Lancet Oncology, The</i> , 2015 , 16, 928-36	21.7	475
165	Cancer surveillance series: interpreting trends in prostate cancer--part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. <i>Journal of the National Cancer Institute</i> , 1999 , 91, 1017-24	9.7	473
164	How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials. <i>Journal of Clinical Oncology</i> , 2002 , 20, 2109-17	2.2	394
163	Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies. <i>Clinical Cancer Research</i> , 2014 , 20, 5322-30	12.9	379
162	Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. <i>Journal of Clinical Oncology</i> , 2000 , 18, 708-15	2.2	377
161	Cancer surveillance series [corrected]: brain and other central nervous system cancers: recent trends in incidence and mortality. <i>Journal of the National Cancer Institute</i> , 1999 , 91, 1382-90	9.7	375
160	Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. <i>Clinical Cancer Research</i> , 2006 , 12, 4899-907	12.9	361
159	A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. <i>Molecular Therapy</i> , 2004 , 10, 958-66	11.7	332
158	Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. <i>Journal of Clinical Oncology</i> , 2003 , 21, 2508-18	2.2	330
157	Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study. <i>Lancet Oncology, The</i> , 2012 , 13, 622-32	21.7	292
156	Clinical trial designs for cytostatic agents: are new approaches needed?. <i>Journal of Clinical Oncology</i> , 2001 , 19, 265-72	2.2	288

155	The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma: a surveillance, epidemiology, and end results analysis. <i>Cancer</i> , 2002 , 95, 1504-10	6.4	251
154	Age, sex, and racial differences in the use of standard adjuvant therapy for colorectal cancer. <i>Journal of Clinical Oncology</i> , 2002 , 20, 1192-202	2.2	236
153	Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999. <i>Archives of Pathology and Laboratory Medicine</i> , 2000 , 124, 995-1000	5	201
152	Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. <i>Lancet Oncology, The</i> , 2011 , 12, 642-53	21.7	200
151	Prognostic indicators of colon tumors. The Gastrointestinal Tumor Study Group experience. <i>Cancer</i> , 1986 , 57, 1866-70	6.4	175
150	Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naïve adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. <i>Lancet, The</i> , 2018 , 392, 1413-1425	40	175
149	Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2016 , 387, 1066-1074	40	170
148	Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301. <i>Journal of Clinical Oncology</i> , 2006 , 24, 3354-60	2.2	158
147	Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. <i>Journal of Clinical Oncology</i> , 2002 , 20, 2277-83	2.2	156
146	Focal Ablation Targeted to the Index Lesion in Multifocal Localised Prostate Cancer: a Prospective Development Study. <i>European Urology</i> , 2015 , 68, 927-36	10.2	126
145	A Multicentre Study of 5-year Outcomes Following Focal Therapy in Treating Clinically Significant Nonmetastatic Prostate Cancer. <i>European Urology</i> , 2018 , 74, 422-429	10.2	122
144	Morphologic effect of dimethyl sulfoxide on the blood-brain barrier. <i>Science</i> , 1982 , 217, 164-6	33.3	120
143	Speeding up the evaluation of new agents in cancer. <i>Journal of the National Cancer Institute</i> , 2008 , 100, 1204-14	9.7	109
142	Long-term survival in patients with malignant astrocytoma. <i>Neurosurgery</i> , 1994 , 34, 213-9; discussion 219-20	3.2	109
141	Optimising the Diagnosis of Prostate Cancer in the Era of Multiparametric Magnetic Resonance Imaging: A Cost-effectiveness Analysis Based on the Prostate MR Imaging Study (PROMIS). <i>European Urology</i> , 2018 , 73, 23-30	10.2	105
140	Evaluating many treatments and biomarkers in oncology: a new design. <i>Journal of Clinical Oncology</i> , 2013 , 31, 4562-8	2.2	105
139	A prospective study of topical dimethyl sulfoxide for treating anthracycline extravasation. <i>Journal of Clinical Oncology</i> , 1988 , 6, 1732-5	2.2	95
138	A new GWAS and meta-analysis with 1000Genomes imputation identifies novel risk variants for colorectal cancer. <i>Scientific Reports</i> , 2015 , 5, 10442	4.9	94

137	Effect of age and reoperation on survival in the combined modality treatment of malignant astrocytoma. <i>Neurosurgery</i> , 1982 , 10, 454-63	3.2	91
136	Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIg phase 3 randomised controlled trial. <i>Lancet, The</i> , 2019 , 394, 2084-2095	4.0	88
135	Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2012 , 38, 618-25	14.4	85
134	Brain-blood barrier? Yes and no. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1983 , 80, 7352-6	11.5	84
133	Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus-1 Infection: Week 48 Results of the DRIVE-AHEAD Trial. <i>Clinical Infectious Diseases</i> , 2019 , 68, 535-544	11.6	84
132	Association analyses identify 31 new risk loci for colorectal cancer susceptibility. <i>Nature Communications</i> , 2019 , 10, 2154	17.4	81
131	Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial. <i>Lancet Oncology, The</i> , 2014 , 15, 631-9	21.7	81
130	Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy ± cetuximab. <i>Clinical Cancer Research</i> , 2013 , 19, 4104-13	12.9	72
129	Patterns of care for the treatment of bladder cancer. <i>Journal of Urology</i> , 2003 , 169, 1697-701	2.5	70
128	Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial. <i>Lancet Infectious Diseases, The</i> , 2019 , 19, 253-264	25.5	65
127	High hospital research participation and improved colorectal cancer survival outcomes: a population-based study. <i>Gut</i> , 2017 , 66, 89-96	19.2	64
126	Early-Medium-Term Outcomes of Primary Focal Cryotherapy to Treat Nonmetastatic Clinically Significant Prostate Cancer from a Prospective Multicentre Registry. <i>European Urology</i> , 2019 , 76, 98-105 ^{10.2}	10.2	63
125	Bevacizumab May Differentially Improve Ovarian Cancer Outcome in Patients with Proliferative and Mesenchymal Molecular Subtypes. <i>Clinical Cancer Research</i> , 2017 , 23, 3794-3801	12.9	62
124	The National Cancer Institute audit of the National Surgical Adjuvant Breast and Bowel Project Protocol B-06. <i>New England Journal of Medicine</i> , 1995 , 333, 1469-74	59.2	59
123	Incremental treatment costs in national cancer institute-sponsored clinical trials. <i>JAMA - Journal of the American Medical Association</i> , 2003 , 289, 2970-7	27.4	57
122	Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience. <i>British Journal of Cancer</i> , 2009 , 100, 251-8	8.7	56
121	Molecular subgroup of high-grade serous ovarian cancer (HGSOC) as a predictor of outcome following bevacizumab.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 5502-5502	2.2	54
120	Mendelian randomisation implicates hyperlipidaemia as a risk factor for colorectal cancer. <i>International Journal of Cancer</i> , 2017 , 140, 2701-2708	7.5	50

119	Common variation at 2q22.3 (ZEB2) influences the risk of renal cancer. <i>Human Molecular Genetics</i> , 2013 , 22, 825-31	5.6	49
118	Medium-term oncological outcomes in a large cohort of men treated with either focal or hemi-ablation using high-intensity focused ultrasonography for primary localized prostate cancer. <i>BJU International</i> , 2019 , 124, 431-440	5.6	48
117	Can we deliver randomized trials of focal therapy in prostate cancer?. <i>Nature Reviews Clinical Oncology</i> , 2014 , 11, 482-91	19.4	47
116	Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study. <i>Health Technology Assessment</i> , 2018 , 22, 1-176	4.4	46
115	Medium-term Outcomes after Whole-gland High-intensity Focused Ultrasound for the Treatment of Nonmetastatic Prostate Cancer from a Multicentre Registry Cohort. <i>European Urology</i> , 2016 , 70, 668-674	19.2	45
114	Exome resequencing identifies potential tumor-suppressor genes that predispose to colorectal cancer. <i>Human Mutation</i> , 2013 , 34, 1026-34	4.7	44
113	Effect of back supports on back strength in patients with osteoporosis: a pilot study. <i>Mayo Clinic Proceedings</i> , 1996 , 71, 235-41	6.4	44
112	Improving cancer outcomes through international collaboration in academic cancer treatment trials. <i>Journal of Clinical Oncology</i> , 2009 , 27, 5109-14	2.2	42
111	Prostate-specific antigen vs. magnetic resonance imaging parameters for assessing oncological outcomes after high intensity-focused ultrasound focal therapy for localized prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017 , 35, 30.e9-30.e15	2.8	40
110	Mendelian randomisation analysis strongly implicates adiposity with risk of developing colorectal cancer. <i>British Journal of Cancer</i> , 2016 , 115, 266-72	8.7	39
109	Testing many treatments within a single protocol over 10 years at MRC Clinical Trials Unit at UCL: Multi-arm, multi-stage platform, umbrella and basket protocols. <i>Clinical Trials</i> , 2017 , 14, 451-461	2.2	38
108	Derived neutrophil lymphocyte ratio is predictive of survival from intermittent therapy in advanced colorectal cancer: a post hoc analysis of the MRC COIN study. <i>British Journal of Cancer</i> , 2016 , 114, 612-5	8.7	37
107	Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2-3 randomised trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2018 , 3, 162-171	18.8	37
106	The Effects of Focal Therapy for Prostate Cancer on Sexual Function: A Combined Analysis of Three Prospective Trials. <i>European Urology</i> , 2016 , 69, 844-51	10.2	33
105	Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial. <i>British Journal of Cancer</i> , 2012 , 107, 1037-43	8.7	33
104	This is a platform alteration: a trial management perspective on the operational aspects of adaptive and platform and umbrella protocols. <i>Trials</i> , 2019 , 20, 264	2.8	31
103	Common genetic variation and survival after colorectal cancer diagnosis: a genome-wide analysis. <i>Carcinogenesis</i> , 2016 , 37, 87-95	4.6	31
102	Strengthening clinical cancer research in the United Kingdom. <i>British Journal of Cancer</i> , 2011 , 104, 1529-34	3.4	31

101	Neoadjuvant therapy in cancer treatment. <i>Cancer</i> , 1993 , 72, 3515-24	6.4	31
100	Dolutegravir-based Antiretroviral Therapy for Patients Coinfected With Tuberculosis and Human Immunodeficiency Virus: A Multicenter, Noncomparative, Open-label, Randomized Trial. <i>Clinical Infectious Diseases</i> , 2020 , 70, 549-556	11.6	30
99	and Locus-Specific Variants Have Different Outcomes on Survival to Colorectal Cancer. <i>Clinical Cancer Research</i> , 2017 , 23, 2742-2749	12.9	29
98	What Type of Prostate Cancer Is Systematically Overlooked by Multiparametric Magnetic Resonance Imaging? An Analysis from the PROMIS Cohort. <i>European Urology</i> , 2020 , 78, 163-170	10.2	28
97	Variation at 2q35 (PNKD and TMBIM1) influences colorectal cancer risk and identifies a pleiotropic effect with inflammatory bowel disease. <i>Human Molecular Genetics</i> , 2016 , 25, 2349-2359	5.6	27
96	GNOSIS: guidelines for neuro-oncology: standards for investigational studies-reporting of phase 1 and phase 2 clinical trials. <i>Neuro-Oncology</i> , 2005 , 7, 425-34	1	26
95	Supratentorial malignant gliomas: risk patterns and therapy. <i>Journal of the National Cancer Institute</i> , 1993 , 85, 690-1	9.7	26
94	Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer. <i>Gynecologic Oncology</i> , 2019 , 152, 53-60	4.9	26
93	Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4064-4075	2.2	25
92	Outcomes of a nurse-managed service for stable HIV-positive patients in a large South African public sector antiretroviral therapy programme. <i>Tropical Medicine and International Health</i> , 2014 , 19, 1029-39	2.3	24
91	Measuring the incremental cost of clinical cancer research. <i>Journal of Clinical Oncology</i> , 2001 , 19, 105-102.2	2.2	24
90	Clinical trial designs for cytostatic agents. <i>Journal of Clinical Oncology</i> , 2001 , 19, 3154-5	2.2	24
89	Posture Training Support: preliminary report on a series of patients with diminished symptomatic complications of osteoporosis. <i>Mayo Clinic Proceedings</i> , 1993 , 68, 1171-6	6.4	24
88	Cyclophosphamide plasma and cerebrospinal fluid kinetics with and without dimethyl sulfoxide. <i>Clinical Pharmacology and Therapeutics</i> , 1982 , 32, 122-8	6.1	24
87	Mother-to-child transmission of HIV in a community-based antiretroviral clinic in South Africa. <i>South African Medical Journal</i> , 2010 , 100, 827-31	1.5	23
86	Analyses of 7,635 Patients with Colorectal Cancer Using Independent Training and Validation Cohorts Show That rs9929218 in CDH1 Is a Prognostic Marker of Survival. <i>Clinical Cancer Research</i> , 2015 , 21, 3453-61	12.9	22
85	A feasibility study testing four hypotheses with phase II outcomes in advanced colorectal cancer (MRC FOCUS3): a model for randomised controlled trials in the era of personalised medicine?. <i>British Journal of Cancer</i> , 2014 , 110, 2178-86	8.7	22
84	Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project. <i>Annals of Oncology</i> , 2015 , 26, 2392-8	10.3	22

83	Expanded role of the cerebrospinal fluid reservoir in neurooncology: indications, causes of revision, and complications. <i>Neurosurgery</i> , 1985 , 17, 600-3	3.2	22
82	Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in antiretroviral-experienced subjects: week 48 analysis of AI438011, a Phase IIb, randomized controlled trial. <i>Antiviral Therapy</i> , 2017 , 22, 215-223	1.6	22
81	Mind the gap? The platform trial as a working environment. <i>Trials</i> , 2019 , 20, 297	2.8	21
80	Genome-wide association study and meta-analysis in Northern European populations replicate multiple colorectal cancer risk loci. <i>International Journal of Cancer</i> , 2018 , 142, 540-546	7.5	21
79	Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial. <i>Lancet HIV,the</i> , 2017 , 4, e486-e494	7.8	21
78	Initial levels of CEA and their rate of change in pancreatic carcinoma following surgery chemotherapy and radiation therapy. <i>Cancer</i> , 1978 , 42, 1472-6	6.4	21
77	Quality of life with cediranib in relapsed ovarian cancer: The ICON6 phase 3 randomized clinical trial. <i>Cancer</i> , 2017 , 123, 2752-2761	6.4	20
76	HIV prevalence and determinants of loss-to-follow-up in adolescents and young adults with tuberculosis in Cape Town. <i>PLoS ONE</i> , 2019 , 14, e0210937	3.7	20
75	Cancer Molecular Analysis Project: weaving a rich cancer research tapestry. <i>Cancer Cell</i> , 2002 , 1, 315-8	24.3	20
74	The impact of the roll-out of rapid molecular diagnostic testing for tuberculosis on empirical treatment in Cape Town, South Africa. <i>Bulletin of the World Health Organization</i> , 2017 , 95, 554-563	8.2	20
73	Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group. <i>European Journal of Cancer</i> , 2018 , 100, 35-45	7.5	20
72	Increasing transfers-out from an antiretroviral treatment service in South Africa: patient characteristics and rates of virological non-suppression. <i>PLoS ONE</i> , 2013 , 8, e57907	3.7	19
71	Systematic analysis of circulating soluble angiogenesis-associated proteins in ICON7 identifies Tie2 as a biomarker of vascular progression on bevacizumab. <i>British Journal of Cancer</i> , 2016 , 115, 228-35	8.7	19
70	Metformin use and risk of cancer in patients with type 2 diabetes: a cohort study of primary care records using inverse probability weighting of marginal structural models. <i>International Journal of Epidemiology</i> , 2019 , 48, 527-537	7.8	18
69	Role of the oxidative DNA damage repair gene OGG1 in colorectal tumorigenesis. <i>Journal of the National Cancer Institute</i> , 2013 , 105, 1249-53	9.7	17
68	Issues in regulatory guidelines for data monitoring committees. <i>Clinical Trials</i> , 2004 , 1, 162-9	2.2	17
67	Diaziquone, 2,5-diaziridinyl-3,6-biscarboethoxyamino-1,4-benzoquinone, plasma and cerebrospinal fluid kinetics. <i>Clinical Pharmacology and Therapeutics</i> , 1982 , 31, 650-5	6.1	17
66	Prostate Specific Antigen Criteria to Diagnose Failure of Cancer Control following Focal Therapy of Nonmetastatic Prostate Cancer Using High Intensity Focused Ultrasound. <i>Journal of Urology</i> , 2020 , 203, 734-742	2.5	16

65	Additional Value of Dynamic Contrast-enhanced Sequences in Multiparametric Prostate Magnetic Resonance Imaging: Data from the PROMIS Study. <i>European Urology</i> , 2020 , 78, 503-511	10.2	16
64	Metformin and cancer in type 2 diabetes: a systematic review and comprehensive bias evaluation. <i>International Journal of Epidemiology</i> , 2017 , 46, 728-744	7.8	15
63	Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy. <i>European Journal of Cancer</i> , 2018 , 102, 31-39	7.5	14
62	Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial. <i>Lancet Oncology</i> , 2020 , 21, 969-977	21.7	13
61	Complexities, pitfalls, and strategies for evaluating brain tumor therapies. <i>Current Opinion in Oncology</i> , 1998 , 10, 175-8	4.2	13
60	Monocyte-derived growth factors for human tumor clonogenic cells. <i>Journal of Leukocyte Biology</i> , 1986 , 40, 381-92	6.5	13
59	Treatment guidelines and early loss from care for people living with HIV in Cape Town, South Africa: A retrospective cohort study. <i>PLoS Medicine</i> , 2017 , 14, e1002434	11.6	13
58	The FOCUS4 design for biomarker stratified trials. <i>Chinese Clinical Oncology</i> , 2015 , 4, 35	2.3	13
57	Focal High-intensity Focussed Ultrasound Partial Gland Ablation for the Treatment of Localised Prostate Cancer: A Report of Medium-term Outcomes From a Single-center in the United Kingdom. <i>Urology</i> , 2019 , 133, 175-181	1.6	12
56	National Cancer Institute Clinical Trials Program in Colorectal Cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 1998 , 42 Suppl, S75-9	3.5	12
55	Phase I clinical and pharmacokinetic study of cyclophosphamide administered by five-day continuous intravenous infusion. <i>Cancer Chemotherapy and Pharmacology</i> , 1986 , 18, 33-8	3.5	12
54	Derived neutrophil to lymphocyte ratio as a prognostic factor in patients with advanced colorectal cancer according to RAS and BRAF status: a post-hoc analysis of the MRC COIN study. <i>Anti-Cancer Drugs</i> , 2017 , 28, 546-550	2.4	11
53	High EMSY expression defines a BRCA-like subgroup of high-grade serous ovarian carcinoma with prolonged survival and hypersensitivity to platinum. <i>Cancer</i> , 2019 , 125, 2772-2781	6.4	11
52	Patients' preferences for adjuvant sorafenib after resection of renal cell carcinoma in the SORCE trial: what makes it worthwhile?. <i>Annals of Oncology</i> , 2018 , 29, 370-376	10.3	11
51	Chemotherapy-free intervals for patients with metastatic colorectal cancer remain an option. <i>Journal of Clinical Oncology</i> , 2010 , 28, e275-6; author reply e277-8	2.2	11
50	Rezum water vapour therapy: promising early outcomes from the first UK series. <i>BJU International</i> , 2020 , 126, 557-558	5.6	11
49	Inhibition of WEE1 Is Effective in - and -Mutant Metastatic Colorectal Cancer: A Randomized Trial (FOCUS4-C) Comparing Adavosertib (AZD1775) With Active Monitoring. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3705-3715	2.2	11
48	Evaluation of functional outcomes after a second focal high-intensity focused ultrasonography (HIFU) procedure in men with primary localized, non-metastatic prostate cancer: results from the HIFU Evaluation and Assessment of Treatment (HEAT) registry. <i>BJU International</i> , 2020 , 125, 853-860	5.6	9

47	Development and internal validation of prediction models for biochemical failure and composite failure after focal salvage high intensity focused ultrasound for local radiorecurrent prostate cancer: Presentation of risk scores for individual patient prognoses. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018 , 36, 13.e1-13.e10	2.8	9
46	Focal HIFU therapy for anterior compared to posterior prostate cancer lesions. <i>World Journal of Urology</i> , 2021 , 39, 1115-1119	4	8
45	The concordance between the volume hotspot and the grade hotspot: a 3-D reconstructive model using the pathology outputs from the PROMIS trial. <i>Prostate Cancer and Prostatic Diseases</i> , 2016 , 19, 258-63	6.2	7
44	HER2-HER3 Heterodimer Quantification by FRET-FLIM and Patient Subclass Analysis of the COIN Colorectal Trial. <i>Journal of the National Cancer Institute</i> , 2020 , 112, 944-954	9.7	7
43	Impact of retrospective data verification to prepare the ICON6 trial for use in a marketing authorization application. <i>Clinical Trials</i> , 2019 , 16, 502-511	2.2	6
42	The Royal College of Physicians Simms Lecture, 6 December 2011: clinical research networks and the benefits of intensive healthcare systems. <i>Clinical Medicine</i> , 2012 , 12, 446-52	1.9	5
41	The American press and political community: reporting in Detroit 1865-1920. <i>Media, Culture and Society</i> , 1997 , 19, 331-355	2.5	5
40	Treatment breaks in first line treatment of advanced colorectal cancer: An individual patient data meta-analysis. <i>Cancer Treatment Reviews</i> , 2021 , 99, 102226	14.4	5
39	Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy: Results of the Randomized FOCUS4-N Trial. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3693-3704	2.2	5
38	Long-Term Survival in Patients with Malignant Astrocytoma. <i>Neurosurgery</i> , 1994 , 34, 213-220	3.2	4
37	Comparison of Transrectal Ultrasound Biopsy to Transperineal Template Mapping Biopsies Stratified by Multiparametric Magnetic Resonance Imaging Score in the PROMIS Trial. <i>Journal of Urology</i> , 2020 , 203, 100-107	2.5	4
36	Comprehensive analysis of colorectal cancer-risk loci and survival outcome: A prognostic role for CDH1 variants. <i>European Journal of Cancer</i> , 2020 , 124, 56-63	7.5	4
35	Pattern Recognition Receptor Polymorphisms as Predictors of Oxaliplatin Benefit in Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2019 , 111, 828-836	9.7	4
34	Diagnostic accuracy of the PROMIS study - AuthorsPreply. <i>Lancet, The</i> , 2017 , 390, 362	4.0	3
33	Cancer Control Outcomes Following Focal Therapy Using High-intensity Focused Ultrasound in 1379 Men with Nonmetastatic Prostate Cancer: A Multi-institute 15-year Experience.. <i>European Urology</i> , 2022 ,	10.2	3
32	The Urological Stethoscope: an essential aide for the modern benign prostatic hyperplasia specialist?. <i>BJU International</i> , 2020 , 125, 632-633	5.6	3
31	BRAF V600E Mutation in First-Line Metastatic Colorectal Cancer: An Analysis of Individual Patient Data From the ARCAD Database. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 1386-1395	9.7	3
30	Outcomes of the RAFT trial: robotic surgery after focal therapy. <i>BJU International</i> , 2021 , 128, 504-510	5.6	3

29	False Positive Multiparametric Magnetic Resonance Imaging Phenotypes in the Biopsy-naïve Prostate: Are They Distinct from Significant Cancer-associated Lesions? Lessons from PROMIS. <i>European Urology</i> , 2021 , 79, 20-29	10.2	3
28	Assessment of Return to Baseline Urinary and Sexual Function Following Primary Focal Cryotherapy for Nonmetastatic Prostate Cancer. <i>European Urology Focus</i> , 2021 , 7, 301-308	5.1	3
27	Resistance to first-line ART and a role for dolutegravir. <i>Lancet HIV</i> , 2018 , 5, e112-e113	7.8	3
26	What Survival Benefits are Needed to Make Adjuvant Sorafenib Worthwhile After Resection of Intermediate- or High-Risk Renal Cell Carcinoma? Clinical Investigators' Preferences in the SORCE Trial. <i>Kidney Cancer</i> , 2018 , 2, 123-131	0.6	3
25	Comprehensive pharmacogenetic profiling of the epidermal growth factor receptor pathway for biomarkers of response to, and toxicity from, cetuximab. <i>Journal of Medical Genetics</i> , 2017 , 54, 567-571	5.8	2
24	How can we improve clinical trials?. <i>Nature Clinical Practice Oncology</i> , 2007 , 4, 206-7		2
23	Conventional radical versus focal treatment for localised prostate cancer: a propensity score weighted comparison of 6-year tumour control. <i>Prostate Cancer and Prostatic Diseases</i> , 2021 , 24, 1120-1128	6.3	2
22	Prognostic and Predictive Impact of Primary Tumor Sidedness for Previously Untreated Advanced Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2021 ,	9.7	2
21	An Exploratory Study of Dose Escalation Standard Focal High-Intensity Focused Ultrasound for Treating Nonmetastatic Prostate Cancer. <i>Journal of Endourology</i> , 2020 , 34, 641-646	2.7	2
20	Genome-wide association studies of toxicity to oxaliplatin and fluoropyrimidine chemotherapy with or without cetuximab in 1800 patients with advanced colorectal cancer. <i>International Journal of Cancer</i> , 2021 , 149, 1713-1722	7.5	2
19	Discordance between the results and conclusions of ICON7 - Authors' Reply. <i>Lancet Oncology</i> , 2015 , 16, e478-9	21.7	1
18	Transient traumatic quadriplegia in a 29-year-old man without predisposing anatomic lesion. <i>Archives of Physical Medicine and Rehabilitation</i> , 1995 , 76, 1006-10	2.8	1
17	Experiences of running a stratified medicine adaptive platform trial: Challenges and lessons learned from 10 years of the FOCUS4 trial in metastatic colorectal cancer.. <i>Clinical Trials</i> , 2022 , 17407745211069879	2.2	1
16	A genome-wide search for determinants of survival in 1926 patients with advanced colorectal cancer with follow-up in over 22,000 patients. <i>European Journal of Cancer</i> , 2021 , 159, 247-258	7.5	1
15	A critical evaluation of visual proportion of Gleason 4 and maximum cancer core length quantified by histopathologists. <i>Scientific Reports</i> , 2020 , 10, 17177	4.9	1
14	Comparing significant prostate cancer detection rates after the introduction of pre-biopsy MRI: turning PROMIS into action. <i>Journal of Clinical Urology</i> , 2019 , 12, 341-346	0.2	1
13	In-depth Clinical and Biological Exploration of DNA Damage Immune Response as a Biomarker for Oxaliplatin Use in Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021 , 27, 288-300	12.9	1
12	Imaging Modality and Frequency in Surveillance of Stage I Seminoma Testicular Cancer: Results From a Randomized, Phase III, Noninferiority Trial (TRISST).. <i>Journal of Clinical Oncology</i> , 2022 , JCO2101199	2.3	1

11	Efficacy of anti-epidermal growth factor receptor agents in patients with RAS wild-type metastatic colorectal cancer ≥ 70 years.. <i>European Journal of Cancer</i> , 2022 , 163, 1-15	7.5	o
10	Progression-free survival in the ICON8 trial - AuthorsPreply. <i>Lancet, The</i> , 2020 , 396, 757	4.0	o
9	MRI and targeted biopsies compared to transperineal mapping biopsies for targeted ablation in recurrent prostate cancer after radiotherapy: Primary outcomes of the FORECAST trial.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 5009-5009	2.2	o
8	External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2101090	2.2	o
7	Uptake of the multi-arm multi-stage (MAMS) adaptive platform approach: a trial-registry review of late-phase randomised clinical trials.. <i>BMJ Open</i> , 2022 , 12, e055615	3	o
6	Re: Jochen Walz. The "PROMIS" of Magnetic Resonance Imaging Cost Effectiveness in Prostate Cancer Diagnosis? <i>Eur Urol</i> 2018;73:31-2. <i>European Urology</i> , 2018 , 73, e151-e152	10.2	
5	Response. <i>Journal of the National Cancer Institute</i> , 2014 , 106,	9.7	
4	The University College London/Medical Research Council/National Institute of Health Research-Health Technology Assessment PROMIS Trial: An Update. <i>European Urology Focus</i> , 2015 , 1, 212-214	5.1	
3	Individualised Predictions of the Survival Benefit Due to Adjuvant Therapy in a Randomised Trial of Sorafenib after Nephrectomy for Localised Renal Cell Carcinoma. <i>Kidney Cancer</i> , 2020 , 4, 185-195	0.6	
2	AUTHOR REPLY. <i>Urology</i> , 2019 , 133, 179-180	1.6	
1	Role for Nucleotide Excision Repair Gene Variants in Oxaliplatin-Induced Peripheral Neuropathy.. <i>JCO Precision Oncology</i> , 2018 , 2, 1-18	3.6	